Table 1.

Baseline biochemical and serological markers, and treatment characteristics of the seven patients included in the study

ID	Baseline				Lamivudine treatment
	HBV DNA (IU/ml)	HBeAg	ALT (IU/ml)	HBV genotype	Type response	Months	HBV DNA (IU/ml)	ALT (IU/ml)	Type mutation	Rescue treatment
1	>108	N	392	D	VBK	48	3.6 × 105	31	M204V	LAM+ADV
2	6.6 × 106	N	167	A2	SVR	24	<20	30	–	–
3	1.2 × 106	N	54	A2	SVR	24	<20	33	–	–
4	>108	P	52	D	VBK	12	6.2 × 106	281	M204IV	LAM+TDF
5	3.3 × 106	N	78	A2	VBK	34	8.3 × 104	401	M204MIV	LAM+ETV
6	>108	P	214	A2	VBK	24	1.3 × 107	93	M204V	LAM+TDF
7	2 × 106	N	117	D	VBK	12	2.2 × 104	103	L180LM	LAM+ADV

SVR, sustained virologic response.